Envoy Medical, Inc. (COCH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenues | 78 | 46 | 56 | 68 |
| Sales and marketing | 361 | 358 | 394 | 497 |
| Research and development | 2,485 | 2,748 | 2,757 | 2,591 |
| General and administrative | 2,068 | 1,821 | 1,692 | 1,595 |
| Cost of goods sold | 234 | 226 | 187 | 245 |
| Total costs and operating expenses | 5,148 | 5,153 | 5,030 | 4,928 |
| Operating loss | -5,070 | -5,107 | -4,974 | -4,860 |
| Interest expense, other | - | - | 264 | 132 |
| Other expense, net | -1 | -11 | 15 | - |
| Interest expense, related party | 624 | 495 | - | - |
| Change in fair value of forward purchase agreement put option liability | - | - | - | - |
| Change in fair value of forward purchase agreement warrant liability | -37 | -421 | 311 | -244 |
| Change in fair value of publicly traded warrant liability | 32 | -194 | 426 | -801 |
| Total other income (expense), net | -620 | 109 | -986 | 913 |
| Net loss | -5,690 | -4,998 | -5,960 | -3,947 |
| Cumulative preferred dividends | 1,252 | 1,238 | - | - |
| Cumulative preferred dividends and undistributed earnings allocated to participating securities b | - | - | 1,380 | - |
| Net loss attributable to common stockholders, basic | -6,942 | -6,236 | -7,340 | -3,948 |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax | - | - | - | -1 |
| Other comprehensive income (loss), net of tax | - | - | - | -1 |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -3,948 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.32 | -0.29 | -0.37 | -0.27 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.32 | -0.29 | -0.37 | -0.27 |
| Weighted-average outstanding, basic (in shares) | 21,383,852 | 21,326,609 | 19,616,362 | 19,599,982 |
| Weighted-average outstanding, diluted (in shares) | 21,383,852 | 21,326,609 | 19,616,362 | 19,599,982 |